Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.47 |
| ▸ | CES1 | P23141 | 5/20 | 0.45 |
| ▸ | CES2 | O00748 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508865 | 0.94 | FAAH (0.43) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL12393190 | 0.87 | CTSK (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8366044 | 0.85 | CTSK (0.41) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2579949 | 0.83 | CTSK (0.44) | CTSK | |
| SCHEMBL12393191 | 0.82 | CTSK (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL12452607 | 0.81 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL24442329 | 0.80 | CTSK (0.46) | CES2CTSK | |
| SCHEMBL5586210 | 0.79 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL14464620 | 0.79 | CTSK (0.42) | CTSK | |
| SCHEMBL20349291 | 0.79 | DNM1 (0.44) | CES1CES2EPHX2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| WO-2020227618-A2 | CONVERGENT LIQUID PHASE SYNTHESES OF OLIGONUCLEOTIDES | BIOGEN MA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | FAAH 2302/4885CES1 1009/4885CES2 2036/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | FAAH 1624/4885CES1 122/4885CES2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.